Form 4 Filing for CRESCENT BIOPHARMA, INC.

This filing details transactions by Fairmount Funds Management LLC and related entities concerning CRESCENT BIOPHARMA, INC. (CBIO). On July 16, 2026, Fairmount Healthcare Fund II L.P., through its manager Fairmount Funds Management LLC, acquired 853,450 ordinary shares at $14.50 per share, bringing their total to 3,601,316 shares. Additionally, the fund acquired 525,897 pre-funded warrants, exercisable at $0.001, with an effective exercise price of $14.499. These warrants are for ordinary shares, with 525,897 underlying shares. The reporting owners, including Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Evan Harwin, are deemed directors by deputization due to Peter Harwin's board position. Fairmount Funds Management LLC, as the investment manager, holds these securities, with Peter Harwin and Tomas Kiselak as its managers. They disclaim beneficial ownership except for their pecuniary interest. The pre-funded warrants have no expiration date but are subject to a 9.99% beneficial ownership limitation upon exercise.